➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
AstraZeneca
Harvard Business School
Dow
Johnson and Johnson

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062546

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 062546 describes ERYC, which is a drug marketed by Mayne Pharma, Parke Davis, Warner Chilcott Llc, Hospira, and Johnson And Johnson, and is included in seven NDAs. It is available from one supplier. Additional details are available on the ERYC profile page.

The generic ingredient in ERYC is erythromycin. There are one hundred and three drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
Summary for 062546
Tradename:ERYC
Applicant:Parke Davis
Ingredient:erythromycin
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 062546

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE, DELAYED REL PELLETS;ORALStrength250MG
Approval Date:Jul 25, 1985TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.